Abstract:In multiple myeloma (MM), the hypoxic environment is an important factor causing tumor inflammation, which is strongly correlated to disease progression and unfavorable outcome by activating the key transcription factor, hypoxia-inducible factor-1 alpha (HIF-1 alpha). Formononetin is the major active ingredient of Astragalus membranaceus, which has been shown to possess anti-inflammatory effect by in vitro and in vivo study. However, the underlying molecular mechanism of whether formononetin inhibits tumor inflammation remains poorly understood. In this study, we investigated the effects of formononetin on expression of HIF-1 alpha, and its downstream target gene pro-inflammatory cytokines, including TNF-alpha, TGF-beta 1, IL-6, and IL-8 in multiple myeloma cell U266. We found that hypoxia induced increase in the level of HIF-1a subunit protein and activated the Akt pathway. Moreover, the treatment with formononetin markedly decreased HIF-1 alpha, TNF-alpha, TGF-beta 1, IL-6, and IL-8 expression under hypoxic condition. Mechanistic studies exhibited that formononetin inhibited the production of HIF-1 alpha by reducing phosphorylation of Akt in U266 cells. Furthermore, in vivo study revealed that intragastric administration of formononetin could suppress tumor volumes by anti-inflammation activity. Taken together, our results identify that formononetin suppresses hypoxia-activated pathway that are linked to MM progression, at least partly, by the inhibition of the Akt signaling pathway. Therefore, formononetin may be a new potent therapeutic agent against MM.

Formononetin Suppresses Hypoxia Inducible Factor-1 Alpha/Inflammatory Cytokines Expression Via Inhibiting Akt Signal Pathway In Multiple Myeloma Cells